These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 7146618)

  • 21. Repeated administration of HA-966 and haloperidol to rats: similar tolerance to striatal dopamine accumulation after HA-966 challenge, but dissimilar effects on striatal [3H]spiperone binding.
    Van der Krogt JA; Van Valkenburg CF; Belfroid RD; Heerkens CB
    Eur J Pharmacol; 1988 Dec; 158(1-2):29-35. PubMed ID: 3220118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unitary dopaminergic receptor composed of cooperatively linked agonist and antagonist sub-unit binding sites.
    Leysen JE
    Commun Psychopharmacol; 1979; 3(6):397-410. PubMed ID: 546588
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment.
    Agnati LF; Fuxe K; Benfenati F; Battistini N; Zini I; Toffano G
    Neurosci Lett; 1983 Oct; 40(3):293-7. PubMed ID: 6646502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of varying the dose of haloperidol during its prolonged administration on the development of tolerance and hypersensitivity in dopamine receptors].
    Zharkovskiĭ AM; Beliakov AV
    Farmakol Toksikol; 1983; 46(5):22-4. PubMed ID: 6628655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between dopamine receptor occupation by spiperone and acetylcholine levels in the rat striatum after long-term haloperidol treatment depends on dopamine innervation.
    Korf J; Sebens JB
    J Neurochem; 1987 Feb; 48(2):516-21. PubMed ID: 2878979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and a comparison with dopamine receptor binding.
    Seiler MP; Markstein R
    Mol Pharmacol; 1982 Sep; 22(2):281-9. PubMed ID: 7144729
    [No Abstract]   [Full Text] [Related]  

  • 28. Sensitive periods for the effect of haloperidol on development of striatal dopamine receptors.
    Rosengarten H; Friedman E; Friedhoff AJ
    Birth Defects Orig Artic Ser; 1983; 19(4):511-3. PubMed ID: 6871420
    [No Abstract]   [Full Text] [Related]  

  • 29. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR; Molinoff PB
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
    Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
    Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.
    List SJ; Seeman P
    Life Sci; 1979 Apr; 24(16):1447-52. PubMed ID: 470544
    [No Abstract]   [Full Text] [Related]  

  • 33. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S; Paulose CS; Mishra RK
    Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonism by supidimide of haloperidol-induced augmentation of [3H]-spiperone binding in rat striatum.
    Hennies HH; Hess V; Flohé L
    Arzneimittelforschung; 1984; 34(11):1481-4. PubMed ID: 6543122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
    Severson JA; Robinson HE; Simpson GM
    Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prenatal haloperidol alters striatal dopamine and opiate receptors.
    Moon SL
    Brain Res; 1984 Dec; 323(1):109-13. PubMed ID: 6098328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
    Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
    Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment.
    Roberts RC; Force M; Kung L
    Synapse; 2002 Aug; 45(2):78-85. PubMed ID: 12112400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat.
    Simpson MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1986 Oct; 35(20):3501-6. PubMed ID: 3768037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of ethanol and haloperidol on dopamine receptor (D2) density.
    Fuchs V; Coper H; Rommelspacher H
    Neuropharmacology; 1987 Aug; 26(8):1231-3. PubMed ID: 3658125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.